The Use of Botulinum Toxin A as an Adjunctive Therapy in the Management of Chronic Musculoskeletal Pain : A Systematic Review with Meta-Analysis
(2021) In Toxins 13(9). p.1-17- Abstract
Several studies have investigated the effect of botulinum toxin A (BoNT-A) for managing chronic musculoskeletal pain, bringing contrasting results to the forefront. Thus far, however, there has been no synthesis of evidence on the effect of BoNT-A as an adjunctive treatment within a multimodal approach. Hence, Medline via PubMed, EMBASE, and the Cochrane Library-CENTRAL were searched until November 2020 for randomised controlled trials (RCTs) that investigated the use of BoNT-A as an adjunctive therapy for chronic musculoskeletal pain. The risk of bias (RoB) and the overall quality of the studies were assessed through RoB 2.0 and the GRADE approach, respectively. Meta-analysis was conducted to analyse the pooled results of the six... (More)
Several studies have investigated the effect of botulinum toxin A (BoNT-A) for managing chronic musculoskeletal pain, bringing contrasting results to the forefront. Thus far, however, there has been no synthesis of evidence on the effect of BoNT-A as an adjunctive treatment within a multimodal approach. Hence, Medline via PubMed, EMBASE, and the Cochrane Library-CENTRAL were searched until November 2020 for randomised controlled trials (RCTs) that investigated the use of BoNT-A as an adjunctive therapy for chronic musculoskeletal pain. The risk of bias (RoB) and the overall quality of the studies were assessed through RoB 2.0 and the GRADE approach, respectively. Meta-analysis was conducted to analyse the pooled results of the six included RCTs. Four were at a low RoB, while two were at a high RoB. The meta-analysis showed that BoNT-A as an adjunctive therapy did not significantly decrease pain compared to the sole use of traditional treatment (SDM -0.89; 95% CI -1.91; 0.12; p = 0.08). Caution should be used when interpreting such results, since the studies displayed very high heterogeneity (I = 94%, p < 0.001). The overall certainty of the evidence was very low. The data retrieved from this systematic review do not support the use of BoNT-A as an adjunctive therapy in treating chronic musculoskeletal pain.
(Less)
- author
- Battista, Simone LU ; Buzzatti, Luca ; Gandolfi, Marialuisa ; Finocchi, Cinzia ; Falsiroli Maistrello, Luca ; Viceconti, Antonello ; Giardulli, Benedetto and Testa, Marco
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- in
- Toxins
- volume
- 13
- issue
- 9
- article number
- 640
- pages
- 1 - 17
- publisher
- MDPI AG
- external identifiers
-
- scopus:85115269802
- pmid:34564644
- ISSN
- 2072-6651
- DOI
- 10.3390/toxins13090640
- language
- English
- LU publication?
- no
- id
- 3f641855-15ff-4f14-8738-27f6a02c3972
- date added to LUP
- 2021-11-15 12:50:10
- date last changed
- 2024-07-28 00:47:51
@article{3f641855-15ff-4f14-8738-27f6a02c3972, abstract = {{<p>Several studies have investigated the effect of botulinum toxin A (BoNT-A) for managing chronic musculoskeletal pain, bringing contrasting results to the forefront. Thus far, however, there has been no synthesis of evidence on the effect of BoNT-A as an adjunctive treatment within a multimodal approach. Hence, Medline via PubMed, EMBASE, and the Cochrane Library-CENTRAL were searched until November 2020 for randomised controlled trials (RCTs) that investigated the use of BoNT-A as an adjunctive therapy for chronic musculoskeletal pain. The risk of bias (RoB) and the overall quality of the studies were assessed through RoB 2.0 and the GRADE approach, respectively. Meta-analysis was conducted to analyse the pooled results of the six included RCTs. Four were at a low RoB, while two were at a high RoB. The meta-analysis showed that BoNT-A as an adjunctive therapy did not significantly decrease pain compared to the sole use of traditional treatment (SDM -0.89; 95% CI -1.91; 0.12; p = 0.08). Caution should be used when interpreting such results, since the studies displayed very high heterogeneity (I = 94%, p < 0.001). The overall certainty of the evidence was very low. The data retrieved from this systematic review do not support the use of BoNT-A as an adjunctive therapy in treating chronic musculoskeletal pain.</p>}}, author = {{Battista, Simone and Buzzatti, Luca and Gandolfi, Marialuisa and Finocchi, Cinzia and Falsiroli Maistrello, Luca and Viceconti, Antonello and Giardulli, Benedetto and Testa, Marco}}, issn = {{2072-6651}}, language = {{eng}}, number = {{9}}, pages = {{1--17}}, publisher = {{MDPI AG}}, series = {{Toxins}}, title = {{The Use of Botulinum Toxin A as an Adjunctive Therapy in the Management of Chronic Musculoskeletal Pain : A Systematic Review with Meta-Analysis}}, url = {{http://dx.doi.org/10.3390/toxins13090640}}, doi = {{10.3390/toxins13090640}}, volume = {{13}}, year = {{2021}}, }